Search results for: 'cea and ngs'

The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiol...

Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such a...

20 Jun 2017  |  North America  |  Market Research

Transformation and Growth Opportunities in the US Next-Generation Sequencing Informatics Market

Pharmaceutical and Molecular Diagnostics Segments to Lead Revenue Growth

Infographics

×

Frost & Sullivan expects strong demand for commercial application-focused solutions to drive new investments in the development of tools and technologies, and will also result in consolidation of the US next-generation sequencing informatics market. Changing customer requirements and intense competition will drive the transformation. As companies l...

17 Jul 2017  |  North America  |  Market Research

US Oncology Diagnostics Market, Forecast to 2021

Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection

Infographics

×

Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolida...

Predictive genetic testing (PGT) comprises analysis of genes, the whole genome, or exomes to predict the risk of a wide range of disorders. It can have long-term implications in preventive healthcare practices, including delayed onset of disease, treatment management, pharmacogenomics, and general wellness. One outcome of the COVID-19 pandemic has ...

This research service offers a comprehensive analysis of the global genetic testing industry (specifically, germline genetic testing, which analyzes inherited genetic variations present in an individual from birth and can be passed to offspring). The industry growth is driven by a shift towards preventive care, rising maternal ages, increasing gove...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

Interest in the microbiome as a science and industry has exploded over the past decade. Innovations are happening across 3 significant categories for human health benefits: microbiome-based therapeutics, over-the-counter (OTC) dietary supplements, and self-diagnostics/screening. The OTC market is the largest because of the lack of precise regulatio...